While studying the response of KRAS-mutant lung cancer models to KRASG12C or MEK inhibitors combined with BH3 mimetics, we unexpectedly observed an association between the presence of STK11 mutations and dependence on MCL-1. This evidence concerns the gene MAP2K7 and lung cancer.